Sponsored by Boehringer Ingelheim
Study Locations (as of Jan. 3, 2017): (Recruiting) Vancouver,BC; Hamilton, ON; Halifax, NS. (Not yet recruiting) Edmonton, AB; Toronto, ON.
Sponsored by Hoffman-La Roche — Pirfenidone and Nintedanib are anti-fibrotic drugs that are administered orally.
Study Locations (as of Nov. 1, 2016): Calgary, AB; Toronto, ON.
Sponsored by University of British Columbia
Collaborator Boehringer Ingelheim
Study Locations as of May 4, 2016: (Recruiting) St. Paul’s Hospital, Vancouver, BC (Not yet recruiting) Vancouver General Hospital, Vancouver, BC; UBC Okanagan, Kelowna, BC; University of Calgary, AB; University of Alberta, Edmonton, AB; McMaster University, Hamilton, ON; Queen’s University, Kingston, ON; McGaill University, Montreal, QC; Laval University, Quebec City, QC
Sponsored by FibroGen — intravenous infusion every 3 weeks.
Study Locations as of July 28, 2016:
Quebec City, QC (Recruiting)
Université de Sherbrooke / Hôpital Charles LeMoyne
Quebec City, Canada, J4V2H1
Contact: Nadim Srour, M.D. 450-466-5000 ext 3834 email@example.com
Contact: Geneviève Bujold, R.N. 450-466-5000 ext 2164 firstname.lastname@example.org
Principal Investigator: Nadim Srour, M.D
Institut universitaire de Cardiologie et de Pneumologie de Québec
Quebec city, Quebec, Canada, G1V 4G5
Contact: Steeve Provencher, M.D. 418-656-4747 email@example.com
Contact: Luce Bouffard 418-656-8711 ext 2499 firstname.lastname@example.org
Principal Investigator: Steeve Provencher, M.D.
Study Locations: Please click on above link for numerous locations.
Sponsored by Sanofi — SAR156597 is a bispecific monoclonal antibody against interleukin (IL)-4 and IL-13, two molecules that have been implicated as mediators of IPF development that is administered by subcutaneous injection either once weekly or once every two weeks.
Study Locations: ONGOING BUT NO LONGER RECRUITING Vancouver, BC; Edmonton, AB; and Toronto, ON.
Sponsored by Boehringer Ingelheim — Nintedanib and Pirfenidone are anti-fibrotic drugs that are administered orally. 2 arms: Nintendanib alone and Nintedanib + Pirfenidone
Study Locations: ONGOING BUT NO LONGER RECRUITING Winnipeg, MB and Vancouver, BC.
Sponsored by ProMetic BioSciences Inc. — PBI-4050 is an anti-fibrotic that is administered orally.
Study Locations (updated Oct 13/16): ONGOING BUT NO LONGER RECRUITING Vancouver, BC; Toronto, ON; Montreal and Sherbrooke, QC; and Halifax, NS are recruiting. Check back here or at the link above as 3 other Canadian sites are anticipated.
Sponsored by Hoffmann-La Roche — Lebrikizumab is an antibody that is dissolved in solution like water that can be injected under your skin. It attaches to interlukin-13 (IL-13); it is believed that IL-13 may play a role in IPF. The study is looking at whether blocking IL-13 will slow the progression of the disease.
This is now a combination therapy trial with 4 arms. Treatment A = Lebrikizumab and Treat B = Pirfenidone + Lebrikizumab with each treatment arm having a complementary placebo arm.
Study Locations (updated Sep 2016): (Completed) Vancouver, BC (Active, not recruiting) London, ON; Hamilton, ON; Ste. Foy, QC. (Terminated) Moncton, NB
Sponsored by Boehringer Ingelheim
Study Locations (as of Mar. 8, 2017): (Recruiting) Winnipeg, MB; Hamilton, ON (Not yet recruiting) Toronto, ON; Sherbrooke, QC.
Sponsored by Boehringer Ingelheim — 150 mg capsule twice a day.
Study Locations as of Jan. 3, 2017: (Recruiting) Edmonton, AB; Hamilton, ON; Montreal, QC (Not yet recruiting) Toronto, ON
Sponsored by EMD Serono Research & Development Institute, Inc.
Collaborator Merck KGaA
The purpose of this trial is to compare two doses of abituzumab with placebo and determine whether abituzumab is more effective, safer, will be better tolerated and can provoke better immune response than placebo in the treatment of patients with SSc-ILD who already receive constant doses of mycophenolate.
Intravenous infusion over approximately 1 hour every 4 weeks for 104 weeks with either 1500 mg Abituzumab or 500 mg Abituzumab or placebo
Study Locations as of Aug. 9, 2016: (Not yet recruiting) Vancouver, BC; Toronto, ON